Fenretinide
Fenretinide is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
42 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | 1 | — | — | 3 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Psychotic disorders | D011618 | F20.81 | — | — | 1 | — | — | 1 | |
| Cognition | D003071 | EFO_0003925 | — | — | 1 | — | — | 1 | |
| Urinary bladder neoplasms | D001749 | C67 | — | — | 1 | — | — | 1 | |
| Precancerous conditions | D011230 | — | — | 1 | — | — | 1 | ||
| Uterine cervical neoplasms | D002583 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | 4 | 1 | — | — | 1 | 6 | |
| Head and neck neoplasms | D006258 | 1 | 3 | — | — | — | 4 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | 2 | 3 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 2 | 1 | — | — | — | 2 | |
| T-cell lymphoma peripheral | D016411 | C84.9 | 1 | 1 | — | — | — | 2 | |
| Prostatic neoplasms | D011471 | C61 | — | 2 | — | — | — | 2 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | 1 | — | — | — | 1 | |
| Hodgkin disease | D006689 | C81 | 1 | 1 | — | — | — | 1 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | 1 | 1 | — | — | — | 1 | |
| Follicular lymphoma | D008224 | C82 | 1 | 1 | — | — | — | 1 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 7 | — | — | — | — | 7 | |
| Lymphoma | D008223 | C85.9 | 2 | — | — | — | — | 2 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | — | — | — | — | 1 | |
| Sezary syndrome | D012751 | C84.1 | 1 | — | — | — | — | 1 | |
| T-cell lymphoma | D016399 | 1 | — | — | — | — | 1 | ||
| Mycosis fungoides | D009182 | C84.0 | 1 | — | — | — | — | 1 | |
| T-cell lymphoma cutaneous | D016410 | C84.A | 1 | — | — | — | — | 1 | |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | C95 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FENRETINIDE |
| INN | fenretinide |
| Description | 4-hydroxyphenyl retinamide is a retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids. It has a role as an antineoplastic agent and an antioxidant. It is a retinoid and a monocarboxylic acid amide. It is functionally related to an all-trans-retinoic acid. |
| Classification | Small molecule |
| Drug class | retinol derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1 |
Identifiers
| PDB | — |
| CAS-ID | 65646-68-6 |
| RxCUI | 24870 |
| ChEMBL ID | CHEMBL7301 |
| ChEBI ID | 42588 |
| PubChem CID | 5288209 |
| DrugBank | DB05076 |
| UNII ID | 187EJ7QEXL (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,236 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
27 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more